We are pleased to advise you that the research conducted by the Anaesthesia research group at Fisher and Paykel Healthcare has been published in the Anaesthesia journal.
Several clinical studies (Patel & Nouraei 2015, Gustafsson et. al. 2017, Hengen et. al. 2017 and To et. al. 2017) showed that THRIVE blunts the rate of rise of CO2 in apneoic patients. This is the first paper that demonstrates how and why THRIVE clears CO2 during apneoa.
This physiological study used three laboratory airway models to investigate mechanisms of CO2 clearance in apnoeic patients. Findings suggest that CO2 clearance during THRIVE is mediated by the interaction between supraglottic flow vortices caused by high flow and cardiogenic oscillations.
Fisher and Paykel Healthcare values evidence-based practice to improve patient care and outcomes.
Hermez, L. A., Spence, C. J., Payton, M. J., Nouraei, S. A. R., Patel, A., & Barnes, T. H. (2019). A physiological study to determine the mechanism of carbon dioxide clearance during apnoea when using transnasal humidified rapid insufflation ventilatory exchange (THRIVE). Anaesthesia, 74(4), 441-449.
Optiflow THRIVE, Optiflow and AIRVO2 are trademarks of Fisher & Paykel Healthcare Limited. For patent information, see fphcare.com/ip